The EGFR tyrosine kinase inhibitor (TKI) gefitinib was approved for the treatment of NSCLC in Japan in January 2002, and activating somatic mutations in EGFR, conferring sensitivity to EGFR TKIs were discovered in 2004 (3). Here, EGFR is linked to non-small cell lung carcinoma.